Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment.

Vikelis M, Argyriou AA, Dermitzakis EV, Spingos KC, Makris N, Kararizou E.

J Headache Pain. 2018 Sep 17;19(1):87. doi: 10.1186/s10194-018-0918-3.

2.

A new era in headache treatment.

Vikelis M, Spingos KC, Rapoport AM.

Neurol Sci. 2018 Jun;39(Suppl 1):47-58. doi: 10.1007/s10072-018-3337-y. Review.

PMID:
29904827
3.

Clinical experience with transcutaneous supraorbital nerve stimulation in patients with refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study.

Vikelis M, Dermitzakis EV, Spingos KC, Vasiliadis GG, Vlachos GS, Kararizou E.

BMC Neurol. 2017 May 18;17(1):97. doi: 10.1186/s12883-017-0869-3.

4.

Onabotulinumtoxin-A treatment in Greek patients with chronic migraine.

Vikelis M, Argyriou AA, Dermitzakis EV, Spingos KC, Mitsikostas DD.

J Headache Pain. 2016 Dec;17(1):84. doi: 10.1186/s10194-016-0676-z. Epub 2016 Sep 17.

5.

The iontophoretic transdermal system formulation of sumatriptan as a new option in the acute treatment of migraine: a perspective.

Vikelis M, Spingos KC, Rapoport AM.

Ther Adv Neurol Disord. 2015 Jul;8(4):160-5. doi: 10.1177/1756285615585918. Review. Erratum in: Ther Adv Neurol Disord. 2015 Nov;8(6):339.

Supplemental Content

Loading ...
Support Center